Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Shirley Collie, Jared Champion, Harry Moultrie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 5, pp. 494-496
Open Access | Times Cited: 440

Showing 1-25 of 440 citing articles:

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1226
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 1011
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Adam S. Lauring, Mark W. Tenforde, James D. Chappell, et al.
BMJ (2022), pp. e069761-e069761
Open Access | Times Cited: 595
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
Shabir A. Madhi, Gaurav Kwatra, Jonathan E. Myers, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 14, pp. 1314-1326
Open Access | Times Cited: 389
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 625-626
Open Access | Times Cited: 332
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
Martina McMenamin, Joshua Nealon, Yun Lin, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 10, pp. 1435-1443
Open Access | Times Cited: 320
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes
Sarah A. Buchan, Hannah Chung, Kevin A. Brown, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232760-e2232760
Open Access | Times Cited: 283
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1899-1909
Open Access | Times Cited: 227
Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation
Brit Long, Brandon M Carius, Summer Chavez, et al.
The American Journal of Emergency Medicine (2022) Vol. 54, pp. 46-57
Open Access | Times Cited: 225
Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
Waasila Jassat, Salim S. Abdool Karim, Caroline Mudara, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 7, pp. e961-e969
Open Access | Times Cited: 188
Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022
Anastasia S. Lambrou, Philip Shirk, Molly Steele, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 6, pp. 206-211
Open Access | Times Cited: 185
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 179
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 178
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Khadija Khan, Farina Karim, Yashica Ganga, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 160
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 134
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
Julia Stowe, Nick Andrews, Freja Kirsebom, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 131
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 129
COVID-19 2022 update: transition of the pandemic to the endemic phase
Michela Biancolella, Vito Luigi Colona, Ruty Mehrian‐Shai, et al.
Human Genomics (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 120
Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines
Yannic C. Bartsch, Xin Tong, Jaewon Kang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 642
Open Access | Times Cited: 116
Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel
Paul Kuodi, Yanay Gorelik, Hiba Zayyad, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 114
SARS‐CoV‐2 variants and vulnerability at the global level
Vivek P. Chavda, Aayushi Patel, Darsh D. Vaghasiya
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2986-3005
Open Access | Times Cited: 113
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
Ryutaro Kotaki, Yu Adachi, Saya Moriyama, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 112
SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
Danyi Ao, Tianxia Lan, Xuemei He, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 109
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
Simone I. Richardson, Vimbai Sharon Madzorera, Holly Spencer, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 6, pp. 880-886.e4
Open Access | Times Cited: 107
SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance
Yifei Guo, Jiajia Han, Yao Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 103
Page 1 - Next Page

Scroll to top